10-K: Vycor Medical Reports Increased Revenue, Faces Going Concern Uncertainty in 2024 10-K Filing

Vycor Medical's 2024 10-K filing reveals a revenue increase driven by US sales, but also highlights concerns about the company's ability to continue as a going concern due to accumulated losses and working capital deficiency.

Summary

• Vycor Medical, Inc. reported its Form 10-K for the fiscal year ended December 31, 2024.
• The company operates two business units: Vycor Medical, focused on neurosurgical devices, and NovaVision, providing vision rehabilitation therapies.
• Vycor Medical's revenue increased by 10% to $1,515,744 in 2024, driven by a 17% increase in US hospital sales.
• NovaVision's revenue decreased by 10% to $73,580 in 2024.
• The company recorded a net loss of $107,200 for 2024, compared to a net loss of $69,691 in 2023.
• The company has a working capital deficiency of $3,800,824 as of December 31, 2024, including related party liabilities of $3,298,728.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company is pursuing strategies to reduce cash operating losses and may seek additional funding through debt or equity securities.
• The company's internal control over financial reporting was not effective as of December 31, 2024 due to the lack of a functioning audit committee with independent members.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While revenue increased for Vycor Medical, the company is still operating at a loss and faces significant financial challenges, including a going concern uncertainty and ineffective internal controls. The sentiment is therefore cautiously negative.

Positives

• Vycor Medical's revenue increased by 10% to $1,515,744 in 2024, driven by a 17% increase in US hospital sales, indicating successful market penetration.
• Gross margin of 89% was recorded for Vycor Medical for the year ended December 31, 2024.
• Cash provided by operating activities was $60,110 for the year ended December 31, 2024.

Negatives

• NovaVision's revenue decreased by 10% to $73,580 in 2024.
• The company recorded a net loss of $107,200 for 2024, compared to a net loss of $69,691 in 2023.
• The company has a working capital deficiency of $3,800,824 as of December 31, 2024, including related party liabilities of $3,298,728.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company's internal control over financial reporting was not effective as of December 31, 2024 due to the lack of a functioning audit committee with independent members.

Risks

• The company's ability to continue as a going concern is uncertain due to accumulated losses and a working capital deficiency.
• The company may not have sufficient cash to meet its needs through March 31, 2026, without additional funding.
• There is no guarantee that Fountainhead will continue to provide working capital funding.
• The company's internal control over financial reporting was not effective as of December 31, 2024 due to the lack of a functioning audit committee with independent members, which could result in a material misstatement in our financial statements in future periods.
• The company is subject to litigation, claims and suits arising in the ordinary course of business.

Future Outlook

The Company is executing on a plan to achieve a reduction in cash operating losses and may consider seeking additional equity or debt funding, although there is no assurance that this would be available on acceptable terms or at all.

Management Comments

• Management is also open to a broad range of alternatives for NovaVision as a whole, which could comprise distribution and marketing partnerships, licensing, merger or sale.
• Management believes that the material weakness set forth did not have an effect on our financial results.

Industry Context

The company operates in the medical device industry, with a focus on neurosurgery and vision rehabilitation therapies. The company faces competition from other medical device manufacturers and providers of vision rehabilitation services.

Comparison to Industry Standards

• It is difficult to compare Vycor Medical's results to industry standards due to its small size and specific focus.
• Larger medical device companies such as Medtronic, Johnson & Johnson, and Stryker have significantly higher revenue and market capitalization.
• Smaller companies in the neurosurgery and vision rehabilitation markets may have similar challenges with profitability and access to capital.

Corporate Governance

Legal Proceedings

• The company is subject from time to time to litigation, claims and suits arising in the ordinary course of business.
• As of the date of this Annual Report, we were not a party to any material litigation, claim or suit whose outcome could have a material effect on our financial statements.

Related Party Transactions

• Peter Zachariou and David Cantor, directors of the Company, are investment managers of Fountainhead which owned, at December 31, 2024, 60.9% of the Company's Common Stock and 69.7% of the Company's Series D Preferred Stock.
• Adrian Liddell, Chairman, is a consultant to Fountainhead.
• Peter Zachariou owns 0.15% of the Company's Common Stock and 25.7% of the Company's Series D Preferred Stock.
• During the years ended December 31, 2024 and 2023, respectively, the Company accrued interest on related party loans of $50,013 and $49,515, respectively, and paid accrued interest on related party loans of $35,140 and $0, respectively.
• During each of the years ended December 31, 2024 and 2023, the Company accrued an aggregate of $324,370 of Preferred D Stock dividends, of which $226,036 was regarding Fountainhead and $83,386 was regarding Peter Zachariou.
• Total accrued Preferred D Stock dividends at December 31, 2024 and 2023 was $2,594,960 and $2,270,590, respectively, of which $1,808,296 and $1,582,260, respectively, was regarding Fountainhead and $667,087 and $583,701, respectively, was regarding Peter Zachariou.

Stakeholder Impact

• Shareholders face uncertainty due to the company's going concern status and potential need for additional funding.
• Employees may be affected by potential cost-cutting measures or changes in operations.
• Customers may experience disruptions in service or product availability if the company's financial situation worsens.
• Suppliers and creditors face increased risk of non-payment due to the company's financial challenges.

Next Steps

• The company will continue to execute on a plan to achieve a reduction in cash operating losses.
• The company may consider seeking additional equity or debt funding.
• The company will continue to monitor and manage cybersecurity risks.
• The company will continue to wind down the German operations of NovaVision.

Key Dates

Keywords

Vycor Medical, NovaVision, revenue, net loss, working capital, going concern, medical devices, neurosurgery, vision rehabilitation, internal control, financial statements